Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal

Drug Safety

Volumn 14, Issue 1, 1996, Pages 11-24

  Pedersen, Terje R ^a   Tobert, Jonathan A ^b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COUMARIN ANTICOAGULANT; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; META ANALYSIS; MORTALITY; MYOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK; SURVIVAL;

EID: 0030063062     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199614010-00003     Document Type: Review

References (94)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993; 269: 3015-23
2. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology. European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
4. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from 4S. Am J Cardiol 1995; 76: 64C-68C
5. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274-82
6. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72
7. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 13
8. Thompson SG. Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res 1993; 2: 173-92
9. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia - report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55
10. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419-25
11. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
12. Egger M, Davey Smith G. Misleading meta-analysis. Lessons from 'an effective, safe, simple' intervention that wasn't. BMJ 1995; 310: 752-4
13. Sacks FM, Pfeffer MA, Moye L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991; 68: 1436-46
14. The LIPID Study Management Committee. Lowering cholesterol levels in patients with coronary heart disease. Med J Aust 1995; 162: 455-6
15. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-8
16. Brown G, Albers JJ, Fisher LL, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Fngl J Med 1990; 323: 1289-98
17. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med 1993; 11 (2): 969-76
18. Waters D, Higginson L, Gallstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial. Circulation 1993; 89 (3): 959-68
19. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40
20. Waters D, Craven T, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87: 1067-75
21. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91
22. Vos J, deFeyter I, Simoons ML, et al. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis 1993; 35: 435-54
23. Davies MJ, Krikler DM, Katz D. Atherosclerosis: inhibition or regression as therapeutic possibilities. Br Heart J 1991; 65: 302-10
24. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-8
25. Carvalho ACA, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8
26. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Thromb Vasc Biol 1995; 15: 247-51
27. Kaczmarek D, Hohlfeld T, Wambach G, et al. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. Eur J Clin Pharmacol 1993; 45: 451-7
28. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
29. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-7
30. Seiler C, Hess OM, Buechi M, et al. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation 1993; 88: 2139-48
31. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7
32. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93
33. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500
34. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-87
35. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-5
36. Oliver MF. Doubts about preventing coronary heart disease. Multiple interventions in middle aged men may do more harm than good. BMJ 1992; 304: 393-4
37. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304: 431-4
38. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309-14
39. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol: time to change directions. Circulation 1992; 86: 1026-9
40. Oliver M, Poole-Wilson P, Shepherd J, et al. Lower patients' cholesterol now. BMJ 1995; 310: 1280-1
41. Wood DA. Cholesterol lowering does have a role in secondary prevention. Br Heart J 1995; 73: 4-5
42. Kennedy JW. President's page: expanding the role of the American College of Cardiology. J Am Coll Cardiol 1995; 26: 289-90
43. Smith SC, Blair SN, Criqui MH, et al. AHA consensus panel statement: preventing heart attack and death in patients with coronary disease. Circulation 1995; 92: 2-4
44. Lipid Research Clinics Progam. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
45. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51
46. Chen ZM, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ 1991; 303: 276-82
47. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the utilization of healthcare resources: results of the Scandinavian Simvastatin Survival Study (4S). Circulation. In press
48. Steinhagen-Thiessen E, for the Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of Simvastatin 5 and 10 mg versus pravastatin 10mg in moderate primary hypercholesterolemia. Cardiology 1994; 85: 244-54
49. Douste-Blazy P, Ribeiro VG, Seed M. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolaemia. Drug Invest 1993; 6: 353-61
50. Sweany AE, for the Simvastatin Pravastatin Study Group. A comparison of the efficacy and safety of simvastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 1408-14
51. Lambrecht LJ, Malini PL, and the European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolaemia. Acta Cardiol 1993; 48: 541-54
52. Farmer JA, Washington L, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 1992; 14: 708-77
53. McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992; 14: 276-291
54. Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554-5
55. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-85
56. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacological properties and therapeutic efficacy. Drugs 1995; 50: 334-63
57. Illingworth DR, Stein EA, Knopp RH, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther 1996; 1: 23-30
58. Ose L, Scott R, and the Simvastatin/Fluvastatin Study Group. Double-blind comparison of the efficacy, safety and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995; 10(3): 127-38
59. Mitchel YB, for the Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-5
60. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991; 151: 43-9
61. Berger ML, Wilson HM, Liss CL. A comparison of the tolerability and efficacy of lovastatin 20mg and fluvastatin 20mg in the treatment of primary hypercholesterolemia. J Cardiovasc Pharmacol Ther. In press
62. Jacotot B, Benghazi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol Preprint: 1PR-3PR
63. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J
64. Tobert JA, Shear CL, Chremos AN, et al. Clinical experience with lovastatin. Am J Cardiol 1990; 65: 23F-26F
65. Illingworth DR. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1991; 2: 24-30
66. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69
67. ZOCOR (simvastatin) US product circular, June 1995, Merck & Co. Inc., West Point, PA 19486, USA
68. Feely J, O'Connor P. Effects of HMG-CoA reductase inhibitors on warfarin binding. Drug Invest 1991; 3: 315-6
69. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-8
70. McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993; 15: 57-64
71. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Eng J Med 1995 Sep 7; 333: 664-5
72. Spach DH, Bauwens JE, Clark CD. Rahbdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213-6
73. Ballantyne CM, Radoancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19: 1315-21
74. Barbir M, Rose M, Kushwaha S, et al. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33: 241-6
75. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant patients. Transplantation 1992; 53: 94-9
76. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-20
77. Da Col PG, Fonda M, Fisicaro M, et al. Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemia. Curr Ther Res 1993; 53: 473-83
78. Illingworth DR, Bacon S. The influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 1989; 79: 590-6
79. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 73: 339-45
80. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339-45
81. Stein EA, Davidson MH, Dujovne CA, et al. Combination low dose simvastatin and niacin in patients with combined hyperlipidaemia and low HDL cholesterol: a prospective study comparing lipid altering efficacy and tolerability. J Cardiovasc Pharmacol Ther. In press
82. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
83. Duell PB, Illingworth DR. Combination therapy with HMG-CoA reductase inhibitors and gemfibrozil - practical or perilous? Heart Dis Stroke 1993; 2: 260-2
84. Lovastatin Study Groups I through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993; 153: 1079-87
85. The WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485-91
86. Eckernas SA, Roos BE, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients' with primary moderate hypercholesterolaemia. Br J Clin Pharmacol 1993; 35: 284-9
87. Partinen M, Pihl S, Stranderg TE, et al. Effects on sleep of lovastatin as compared to pravastatin and placebo in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 876-80
88. Kostis JB, Rosen RC, Wilson AC. Central-nervous-system effects of HMG-CoA reductase inhibitors - lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994; 34: 989-96
89. Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231-6
90. Gengo F, Cwudzinski D, Kinkel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995; 18: 209-14
91. Pedersen TR, Kjekshus J, Olsson AG, et al. Scandinavian Simvastatin Survival Study (4S) [letter]. Lancet 1994; 344: 1767-8
92. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
93. Pedersen TR. Lowering cholesterol with drugs and diet. N Engl J Med 1995; 333: 1350-1
94. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64